IPIC Message Board - Msg: 1964201

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC

IPIC 0.0001000

+899.9%

Aug 15 3:35 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Graham Marshman who wrote (559)	8/13/1997 3:15:00 PM
From: Todd D. Wiener	of 1359

The way I see it is that Redux is a good cash flow product for IPIC, even if it's not going to drive earnings. The cash received from Redux sales maintains IPIC's financial strength, while the company continues to develop the products that will eventually boost revenues and earnings. I think that citicoline will be a very big success, and I have little doubt that it will be approved fairly soon after the NDA filing. GNE's Activase is the only real competition, and that's only good for 3 hrs. after a stroke. Citicoline has fewer health risks and is effective for at least 24 hrs. after a stroke. By virtue of the improved safety and efficacy, IPIC's drug should be approved quickly. Todd

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next